Cover Image
市場調查報告書

高血壓治療藥的亞太地區市場

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

出版商 GBI Research 商品編碼 336890
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
Back to Top
高血壓治療藥的亞太地區市場 Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline
出版日期: 2016年12月01日 內容資訊: 英文 110 Pages
簡介

高血壓的盛行率增加,使得醫療費的增加和今後的發病率進一步上升,不過,醫生和患者,一般民眾對疾病的認識也很低,未診斷和未治療的案例變得非常多。高血壓治療藥的亞太地區市場,2015年達到191億美元,估計到2022年以5.1%的年複合成長率(CAGR) 持續增加,同年達到270億美元。高血壓的盛行率成為決定調查對象國家的市場規模的一大要素。市場幾乎由學名藥品獨佔,專利取得產品只有一點點。

本報告提供亞太地區高血壓的治療藥市場相關分析,疾病概要和到目前為止的臨床實驗的進展,主要的已上市產品的特徵,現在臨床實驗中的開發中產品的概要,亞太地區市場趨勢預測 (今後8年份) 等調查評估。

第1章 目錄

第2章 簡介

  • 關於疾病
  • 流行病學
  • 前兆、症狀
  • 病因/病理學
  • 並存症、併發症
  • 診斷
    • 在開業醫生、診所的血壓監測
    • 在門診病人窗口的血壓監測
    • 血壓監測可攜式24小時
    • 家庭的血壓監測
    • 其他技術
    • 特定組織的損傷的診斷
    • 妊娠中的高血壓的診斷
  • 預後
  • 分期
  • 治療方法的選項
    • 治療流程
    • 藥物治療
    • 非藥物治療
  • 第3章 已上市產品
  • 主要的已上市產品
    • 血管收縮素II受體拮抗劑
    • 鈣拮抗劑
    • 腎素抑製劑
    • 血管收縮素轉化酵素抑制劑
    • β- 阻斷劑
    • 複數的藥物級的組合
  • 已上市產品的有效性及安全性比較

第4章 開發中產品分析

  • 概要
  • 各開發階段/各分子類型/各給藥途徑/各計劃類型
  • 分子各標的
  • 有前途的開發平台候補
    • CS-3150

第5章 臨床實驗分析

  • 臨床實驗的失敗率
  • 臨床實驗期間
  • 臨床實驗的規模
  • 競爭性的臨床實驗的評價標準

第6章 各地區市場預測

地理市場 亞太地區市場 ▼印度 治療模式 年度治療費用 市場規模 ▼中國 ▼澳洲 ▼韓國 ▼日本

第7章 市場促進、阻礙因素

  • 推動市場要素
  • 阻礙因素

第8章 資本交易與策略性的市場重組

  • 授權合約
  • 共同開發契約

第9章 附錄

  • 所有開發中產品:各相位
    • 藥物研發階段
    • 前臨床階段
    • 第一階段
    • 第二階段
    • 第三階段
    • 預註冊階段
  • 市場預測 (今後8年份)
    • 亞太地區
    • 印度
    • 中國
    • 澳洲
    • 韓國
    • 日本
  • 參考資料
  • 簡稱集
  • 分析方法
  • 諮詢方式
  • 法律上的免責聲明

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GBIHC426MR

Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke Association (NSA), two-thirds of patients who suffer a stroke have hypertension. The anti-hypertensive therapeutics market is expected to grow significantly over the forecast period across the five Asia-Pacific (APAC) markets, from $19.1 Billion in 2015 to $27 Billion by 2022, at a compound annual growth rate (CAGR) of 5.1%. This growth is primarily attributed to the increasingly elderly population - where the prevalence rate of hypertension is at the highest - and increases in risk factors such as being overweight or obese, high daily sodium intake, low physical activity levels, urbanization, consumption of alcohol, smoking, and mental stress. In the five assessed APAC countries, the total population aged 65 and over was 1 Billion in 2015, and this is expected to grow at a CAGR of 3.32% to reach 1.2 Billion in 2022 (US Census Bureau, 2016).

The antihypertensive pipeline consists of 112 pipeline products, most of which are small molecules. Most of the pipeline products are at early stages of development, with Discovery and Preclinical products accounting for 55%. Phase I, II and III products account for 40%, and Pre-registration products account for 4%. In the five assessed APAC regions, the total estimated prevalence population of hypertension was approximately 548 million in 2015. Of these, approximately 335 million (61.1%) were undiagnosed. Moreover, among the diagnosed patients, approximately 104.7 million (49.1%) were untreated, while 108.5 million (50.9%) were treated with drug therapy. The low diagnosis and treatment rates are primarily due to the lack of awareness of the condition among healthcare professionals, patients, and the public. The asymptomatic nature of the disease is another major factor limiting the diagnosis rate, and a lack of frequent blood pressure checks due to limited affordability and healthcare accessibility in countries such as India and China is another contributing factor.

Moreover, two major marketed products, Benicar/Olmetec (olmesartan medoxomil), and Rasilez (aliskiren), are expected to see their patents expire in Japan and Australia during the forecast period. The patent of Olmetec is expected to expire in Japan in 2016 and Australia in 2017, while the patent of Rasilez (aliskiren) is expected to expire in Australia in 2020. Increasing generic competition across the five APAC regions will restrict market growth during the forecast period.

The report "Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline" provides an introduction to anti-hypertensive, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology, disease staging and prognoses for patients.

In depth, it provides the following:

  • Detailed analysis of the drugs currently marketed for anti-hypertensive (Cozaar, Benicar, Micardis, Diovan, Azilva, Norvasc, Rasilez, Tritace, Carvedilol, Prestalia, Exforge).
  • Provides detailed analysis of the pipeline for anti-hypertensive, by stage of development, molecule type, program type, mechanism of action and molecular target.
  • Detailed analysis of recent clinical trials in this indication, by enrollment, duration and failure rate. Promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
  • Supplies forecasts for the anti-hypertensive markets, including epidemiology, treatment usage patterns, pricing and market size for the 2015-2022 period. The five APAC markets are covered, and data are presented at a country level.
  • Detailed analysis of the key market drivers and barriers for the anti-hypertensive markets.
  • Describes the major deals that have taken place in the global anti-hypertensive markets in recent years. This coverage analyzes licensing and co-development agreements, segmented by stage of development, year, molecule type, mechanism of action and value.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Epidemiology
  • 2.3. Symptoms
  • 2.4. Etiology and Pathophysiology
  • 2.5. Diagnosis
    • 2.5.1. Office or Clinic Blood Pressure Monitoring
    • 2.5.2. Automated Office Blood Pressure Measurement
    • 2.5.3. Ambulatory Blood Pressure Monitoring
    • 2.5.4. Home Blood Pressure Monitoring
    • 2.5.5. Miscellaneous Methods
    • 2.5.6. Diagnosis of Target Organ Damage
    • 2.5.7. Diagnosis of Hypertension in Pregnancy
  • 2.6. Prognosis
  • 2.7. Disease Stage
  • 2.8. Treatment Options
    • 2.8.1. Treatment Algorithm
    • 2.8.2. Pharmacological Treatment
    • 2.8.3. Non-pharmacological Treatment

3. Marketed Products

  • 3.1. Angiotensin II Receptor Antagonists
    • 3.1.1. Losartan - Merck & Co
    • 3.1.2. Olmesartan - Daiichi Sankyo
    • 3.1.3. Olmesartan + Amlodipine + Hydrochlorothiazide - Daiichi Sankyo
    • 3.1.4. Valsartan - Novartis
    • 3.1.5. Telmisartan - Boehringer Ingelheim
    • 3.1.6. Azilsartan Medoxomil - Takeda
  • 3.2. Calcium Channel Blockers
    • 3.2.1. Amlodipine - Pfizer
  • 3.3. Renin Inhibitors
    • 3.3.1. Aliskiren - Novartis
  • 3.4. Angiotensin Converting Enzyme Inhibitors
    • 3.4.1. Ramipril - Sanofi
  • 3.5. Beta Blockers
    • 3.5.1. Carvedilol - GlaxoSmithKline
  • 3.6. Multiple Drug Class Combinations
    • 3.6.1. Perindopril Arginine + Amlodipine Besylate - Les Laboratoires Servier
    • 3.6.2. Amlodipine + Valsartan - Novartis
  • 3.7. Comparative Efficacy and Safety of Marketed Products

4. Pipeline Analysis

  • 4.1. Overview
  • 4.2. Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
  • 4.3. Pipeline by Molecular Target
  • 4.4. Promising Pipeline Candidates
    • 4.4.1. CS-3150

5. Clinical Trial Analysis

  • 5.1. Failure Rate
    • 5.1.1. Overall Failure Rate
    • 5.1.2. Failure Rate by Phase and Molecule Type
    • 5.1.3. Failure Rate by Phase and Molecular Target
  • 5.2. Clinical Trial Duration
    • 5.2.1. Clinical Trial Duration by Molecule Type
    • 5.2.2. Clinical Trial Duration by Molecular Target
  • 5.3. Clinical Trial Size
    • 5.3.1. Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
    • 5.3.2. Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
  • 5.4. Competitive Clinical Trials Metrics Analysis

6. Multi-Scenario Forecast

  • 6.1.1. Geographical Markets
  • 6.1.2. Asia-Pacific Market
  • 6.2. India
    • 6.2.1. Treatment Use Patterns
    • 6.2.2. Annual Cost of Therapy
    • 6.2.3. Market Size
  • 6.3. China
    • 6.3.1. Treatment Use Patterns
    • 6.3.2. Annual Cost of Therapy
    • 6.3.3. Market Size
  • 6.4. Australia
    • 6.4.1. Treatment Use Patterns
    • 6.4.2. Annual Cost of Therapy
    • 6.4.3. Market Size
  • 6.5. South Korea
    • 6.5.1. Treatment Usage Patterns
    • 6.5.2. Annual Cost of Therapy
    • 6.5.3. Market Size
  • 6.6. Japan
    • 6.6.1. Treatment Use Patterns
    • 6.6.2. Annual Cost of Therapy
    • 6.6.3. Market Size

7. Drivers and Barriers

  • 7.1. Drivers
    • 7.1.1. Increasing Aging Populations to Increase Prevalence
    • 7.1.2. Increasing Overweight and Obese Population
    • 7.1.3. Increase in Daily Sodium Intake
    • 7.1.4. Sedentary Lifestyle or Less Physical Activity
    • 7.1.5. High Prevalence of Smoking and Alcoholism
    • 7.1.6. Diversified Healthcare Reform to Boost Market Growth
  • 7.2. Barriers
    • 7.2.1. Weak Pipeline and Widespread Usage of Generic Drugs
    • 7.2.2. Non-pharmacological First-Line Treatment
    • 7.2.3. Lack of Awareness of the Disease Condition

8. Deals and Strategic Consolidations

  • 8.1. Licensing Deals
    • 8.1.1. Deals by Region and Value
    • 8.1.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.1.3. Deal Value by Stage of Development, Molecule Type, and Molecular Target
    • 8.1.4. Key Licensing Deals
  • 8.2. Co-development Deals
    • 8.2.1. Deals by Region and Value
    • 8.2.2. Deal Value by Stage of Development, Molecule Type, and Molecular Target
    • 8.2.3. Deal Value by Stage of Development, Molecule Type, and Molecular Target
    • 8.2.4. Key Co-development Deals

9. Appendix

  • 9.1. All Pipeline Drugs by Stage of Development
    • 9.1.1. Discovery
    • 9.1.2. Preclinical
    • 9.1.3. Investigational New Drug/ Clinical Trial Authorization-Filed
    • 9.1.4. Phase I
    • 9.1.5. Phase II
    • 9.1.6. Phase III
    • 9.1.7. Pre-registration
  • 9.2. Market Forecasts to 2022
    • 9.2.1. Asia-Pacific
    • 9.2.2. India
    • 9.2.3. China
    • 9.2.4. Australia
    • 9.2.5. South Korea
    • 9.2.6. Japan
  • 9.3. Reference
  • 9.4. Abbreviations
  • 9.5. Research Methodology
    • 9.5.1. Secondary Research
    • 9.5.2. Marketed Product Profiles
    • 9.5.3. Late-Stage Pipeline Candidates
    • 9.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 9.5.5. Product Competitiveness Framework
    • 9.5.6. Pipeline Analysis
    • 9.5.7. Forecasting Model
    • 9.5.8. Deals Data Analysis
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Anti-hypertensive Therapeutics, Prevalence Rate
  • Table 2: Anti-hypertensive Therapeutics, Definitions of Hypertension by Office and Out-of-Office Blood Pressure Levels (mmHg)
  • Table 3: Anti-hypertensive Therapeutics, Proposal for Outcome-Driven Reference Values for Ambulatory Blood Pressure Measurement (mmHg)
  • Table 4: Anti-hypertensive Therapeutics, Blood Pressure Stages in Adults (mmHg)
  • Table 5: Anti-hypertensive Therapeutics, Compelling and Possible Contra-indications of Anti-hypertensive Drugs
  • Table 6: Anti-hypertensive Therapeutics, Lifestyle Measures and Recommendations
  • Table 7: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
  • Table 8: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
  • Table 9: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Investigational New Drug, 2016
  • Table 10: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
  • Table 11: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Phase-II, 2016
  • Table 12: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
  • Table 13: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2016
  • Table 14: Anti-hypertensive Therapeutics Market, Asia-Pacific, Market Forecast, 2015-2022
  • Table 15: Anti-hypertensive Therapeutics Market, India, Market Forecast, 2015-2022
  • Table 16: Anti-hypertensive Therapeutics Market, China, Market Forecast, 2015-2022
  • Table 17: Anti-hypertensive Therapeutics Market, Australia, Market Forecast, 2015-2022
  • Table 18: Anti-hypertensive Therapeutics Market, South Korea, Market Forecast, 2015-2022
  • Table 19: Anti-hypertensive Therapeutics Market, Japan, Market Forecast, 2015-2022
  • Table 20: Abbreviations

List of Figures

  • Figure 1: Anti-hypertensive Therapeutics, Global, Hypertension Prevalence Rate (%), 2009-2012
  • Figure 2: Anti-hypertensive Therapeutics, Physiological Mechanism of Renin-Angiotensin-Aldosterone System
  • Figure 3: Anti-hypertensive Therapeutics: Blood Pressure Measurements and Examination of a Patient to Detect Hypertension
  • Figure 4: Anti-hypertensive Therapeutics, Treatment Algorithm of Hypertension
  • Figure 5: Anti-hypertensive Therapeutics, Combination Therapy Strategies for Blood Pressure Reduction
  • Figure 6: Anti-hypertensive Market, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of Hypertension
  • Figure 7: Anti-hypertensive Market, Comparative Efficacy and Safety Heatmap for Marketed Products for Pediatrics for the Treatment of Hypertension
  • Figure 8: Anti-hypertensive Therapeutics Market, Global, Pipeline, 2016
  • Figure 9: Anti-hypertensive Therapeutics Market, Global, Pipeline by Molecular Target, 2016
  • Figure 10: Anti-hypertensive Therapeutics, Global, Pipeline by Molecular Target and Stage of Development, 2016
  • Figure 11: Anti-hypertensive Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2016
  • Figure 12: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type (%), 2006-2015
  • Figure 13: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target (%), 2006-2015
  • Figure 14: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2015
  • Figure 15: Anti-hypertensive Therapeutics, Global, Clinical Trial Duration by Molecular Target, 2006-2015
  • Figure 16: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Trial by Molecular Type, 2006-2015
  • Figure 17: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target, 2006-2015
  • Figure 18: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Molecule Type, 2006-2015
  • Figure 19: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Molecular Target, 2006-2015
  • Figure 20: Anti-hypertensive Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
  • Figure 21: Anti-hypertensive Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Figure 22: Anti-hypertensive Therapeutics Market, Asia-Pacific, Treatment Patterns (million) and Market Size ($bn), 2015-2022
  • Figure 23: Anti-hypertensive Therapeutics Market, India, Treatment Patterns (million), 2015-2022
  • Figure 24: Anti-hypertensive Therapeutics Market, India, Annual Cost of Therapy ($), 2015-2022
  • Figure 25: Anti-hypertensive Therapeutics Market, India, Market Size ($bn), 2015-2022
  • Figure 26: Anti-hypertensive Therapeutics Market, China, Treatment Patterns (million), 2015-2022
  • Figure 27: Anti-hypertensive Therapeutics Market, China, Annual Cost of Therapy ($), 2015-2022
  • Figure 28: Anti-hypertensive Therapeutics Market, China, Market Size ($bn), 2015-2022
  • Figure 29: Anti-hypertensive Therapeutics Market, Australia, Treatment Patterns (million), 2015-2022
  • Figure 30: Anti-hypertensive Therapeutics Market, Australia, Annual Cost of Therapy ($), 2015-2022
  • Figure 31: Anti-hypertensive Therapeutics Market, Australia, Market Size ($bn), 2015-2022
  • Figure 32: Anti-hypertensive Therapeutics Market, South Korea, Treatment Patterns (million), 2015-2022
  • Figure 33: Anti-hypertensive Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022
  • Figure 34: Anti-hypertensive Therapeutics Market, South Korea, Market Size ($bn), 2015-2022
  • Figure 35: Anti-hypertensive Therapeutics Market, Japan, Treatment Patterns (million), 2015-2022
  • Figure 36: Anti-hypertensive Therapeutics Market, Japan, Annual Cost of Therapy ($), 2015-2022
  • Figure 37: Anti-hypertensive Therapeutics Market, Japan, Market Size ($bn), 2015-2022
  • Figure 38: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016
  • Figure 39: Anti-hypertensive Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
  • Figure 40: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
  • Figure 41: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2016
  • Figure 42: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2016
  • Figure 43: Anti-hypertensive Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006-2016
  • Figure 44: Anti-hypertensive Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
  • Figure 45: Anti-hypertensive Therapeutics, Global, Co-development Deals by Phase and Mechanism of Action, 2006-2016
Back to Top